期刊
EUROPEAN JOURNAL OF NEUROLOGY
卷 20, 期 7, 页码 1043-1052出版社
WILEY
DOI: 10.1111/ene.12102
关键词
Alzheimer's disease; brain amyloid-; brain biopsy; flutemetamol; normal pressure hydrocephalus; Pittsburgh compound B; positron emission tomography
资金
- GE Healthcare
- GE Healthcare, Princeton, NJ, USA
- Finnish Medical Foundation
Background and purpose This study determined the correlation between uptake of the amyloid positron emission tomography (PET) imaging agent [18F]flutemetamol and amyloid- measured by immunohistochemical and histochemical staining in a frontal cortical biopsy. Methods Fifteen patients with possible normal pressure hydrocephalus (NPH) and previous brain biopsy obtained during intracranial pressure monitoring underwent [18F]flutemetamol PET. Seven of these patients also underwent [11C] Pittsburgh compound B (PiB) PET. [18F]Flutemetamol and [11C]PiB uptake was quantified using standardized uptake value ratio (SUVR) with the cerebellar cortex as a reference region. Tissue amyloid- was evaluated using the monoclonal antibody 4G8, Thioflavin-S and Bielschowsky silver stain. Results [18F]Flutemetamol and [11C]PiB SUVRs correlated with biopsy specimen amyloid- levels contralateral (r=0.86, P<0.0001; r=0.96, P=0.0008) and ipsilateral (r=0.82, P=0.0002; r=0.87, P=0.01) to the biopsy site. Association between cortical composite [18F]flutemetamol SUVRs and [11C]PiB SUVRs was highly significant (r=0.97, P=0.0003). Conclusions [18F]Flutemetamol detects brain amyloid- in vivo with moderate to high sensitivity and high specificity. This agent, therefore, represents a valuable new tool to study and verify the presence of amyloid- pathology, both in patients with possible NPH and among the wider population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据